Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $27.13

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.13.

A number of research analysts have recently issued reports on KURA shares. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Wedbush raised their price target on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Scotiabank dropped their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. JMP Securities reissued a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, Bank of America dropped their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd.

Kura Oncology Stock Up 1.2 %

Shares of NASDAQ KURA opened at $8.25 on Tuesday. The stock has a market capitalization of $641.21 million, a P/E ratio of -3.49 and a beta of 0.78. The company has a 50-day moving average price of $8.30 and a 200-day moving average price of $14.15. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 over the last three months. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of KURA. nVerses Capital LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after buying an additional 5,788 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 21.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after buying an additional 8,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after buying an additional 7,722 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter valued at approximately $298,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.